Bristol-Myers Squibb (NYSE:BMY) Stock Price Down 0.4%

Shares of Bristol-Myers Squibb (NYSE:BMYGet Free Report) fell 0.4% during mid-day trading on Tuesday . The company traded as low as $40.35 and last traded at $40.81. 4,289,295 shares were traded during mid-day trading, a decline of 72% from the average session volume of 15,357,249 shares. The stock had previously closed at $40.97.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Barclays cut their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $60.00.

View Our Latest Stock Report on BMY

Bristol-Myers Squibb Stock Performance

The stock’s fifty day moving average price is $43.89 and its 200 day moving average price is $48.55. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.05 EPS. As a group, equities analysts predict that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 5.90%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Institutional Investors Weigh In On Bristol-Myers Squibb

A number of hedge funds have recently added to or reduced their stakes in BMY. Northwest Financial Advisors bought a new position in Bristol-Myers Squibb in the fourth quarter valued at about $27,000. ESL Trust Services LLC bought a new position in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. Accordant Advisory Group Inc purchased a new position in shares of Bristol-Myers Squibb in the first quarter worth approximately $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $34,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $40,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Company Profile

(Get Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read More

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.